Highlights

Roth Capital Starts Coverage on AEterna Zentaris (AEZS)

 Source: ABMN Staff   |   Publish date: Thu, 20 Sep 2012, 08:04 AM   |    >> Read article in News website

Research analysts at Roth Capital began coverage on shares of AEterna Zentaris (NASDAQ: AEZS) in a report released on Thursday. The firm set a “buy” rating on the stock.

AEterna Zentaris opened at 0.6801 on Thursday. AEterna Zentaris has a 1-year low of $0.38 and a 1-year high of $2.17. The company’s market cap is $76.4 million.

A number of other firms have also recently commented on AEZS. Analysts at Oppenheimer reiterated a “perform” rating on shares of AEterna Zentaris in a research note to investors on Thursday, August 16th. Analysts at RBC Capital cut their price target on shares of AEterna Zentaris from $0.70 to $0.55 in a research note to investors on Thursday, August 16th. They now have a “sector perform” rating on the stock.

Aeterna Zentaris Inc. (Aeterna Zentaris) is a drug development company specialized in oncology and endocrine therapy.

Share this

  Be the first to like this.
 


 

4908  2415  530  513 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 VXX 15.10-1.71 
 BAC 12.70+0.52 
 SPY 203.20+3.60 
 TVIX 2.56-0.68 
 SIRI 3.83+0.07 
 XLF 21.98+0.53 
 EEM 33.19+0.96 
 UVXY 11.43-3.29 
 BCS 7.30+0.27 
 GDX 26.60-0.46 
Partners & Brokers